摘要
目的观察疏血通注射液治疗活动期类风湿关节炎(RA)临床疗效及不良反应情况。方法治疗组(67例)用常规治疗加疏血通注射液(分6 mL和8 mL)加5%生理盐水250 mL静脉滴注,对照组(30例)只用常规治疗。分别于治疗前,治疗1、2及4周时测定Thompson指数、Ritchie指数、晨僵时间、血沉及纤维蛋白原(Fib),并记录与疏血通注射液相关的不良反应。结果与本组治疗前比较,治疗组治疗后3个时间段上述诸指标明显好转(P<0.01),而对照组治疗4周时才明显好转(P<0.01)。与对照组比较,治疗组各指标各时段改善明显(P<0.05或P<0.01)。疏血通注射液两个剂量组间比较,以8 mL组疗效显著(P<0.01),但疏血通注射液8 mL组有2例患者双手肿胀,1例头胀,1例下肢浮肿,但剂量由每天8 mL改为6 mL后,上述症状好转。结论疏血通注射液治疗活动期RA有效,不良反应少,以8mL剂量疗效比较好。
Objective To observe the efficacy and adverse reaction of Shuxuetong Injection （ SXTI, the extracted liquor from Pheretima and Hirudo） in treating patients with active rheumatoid arthritis （RA）. Methods Ninety-seven patients with active RA assigned in the SXTI group were treated with high or low dose SXTI （6 mL/d or 8 mL/d） combined with conventional therapy and the 30 in the control group treated with conventional therapy alone. Thompson index, Ritchie index, time of morning stiffness （TMS）, erythrocyte sedimentation rate （ESR） and plasma fibrinogen （Fib） in patients were determined before treatment （T0）, by the end of the 1st （T1）, second （T2） and 4th （T3） week of treatment, respectively, as well as the SXTI associated adverse reaction monitored. Results Marked improvement of all indexes, including Thompson index, Ritche index, TMS, ESR and Fib, was shown in the SXTI groups at T1 （P 〈0. 01 ）, but in the control group, it only appeared at T3 （P 〈0. 01 ）. Compared with the control group, TMS, ESR and Fib at T1, Thompson index and Ritche index at T2 in the SXTI groups were significantly improved （P 〈0. 01 ）, especially significant in the high dose group （P 〈0. 01 ）. However, hands edema appeared in 2 patients, foot edema in 1 and fullness sensation of head in 1 in the high dose SXTI a group. The dose was forced to reduc to 6 mL/d, and then all the symptoms were improved. Conclusion SXTI shows good efficacy with less adverse reaction in treating patients with active RA, and better efficacy was obtained at the dose of 8mL/d .
出处
《中国中西医结合杂志》
CAS
CSCD
北大核心
2008年第3期255-257,共3页
Chinese Journal of Integrated Traditional and Western Medicine
